What's Happening?
The integration of digital pathology and artificial intelligence (AI) is transforming the measurement of HER2 protein levels in tumors, crucial for guiding antibody-drug conjugate (ADC) treatments. Traditional
lab tests often miss details in patients with low HER2 expression, but digital tools now allow for more precise measurement, enabling better treatment decisions. This advancement is particularly significant for ADCs like Enhertu, which target HER2-positive or low-expressing cancers. The technology allows for the identification of low and ultra-low responders, improving patient eligibility for targeted therapies.
Why It's Important?
The use of digital pathology and AI in measuring HER2 levels represents a significant advancement in personalized cancer treatment. By accurately identifying patients who can benefit from ADCs, these technologies can improve treatment outcomes and reduce unnecessary side effects. The ability to precisely measure protein expression levels also enhances the development of new therapies and supports more effective clinical trials. As these technologies become more widely adopted, they have the potential to revolutionize cancer care by providing more tailored and effective treatment options.
